We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
BMS, Tibotec combine HCV candidates for all oral direct-acting antiretroviral regimen
19 Apr 2012
Executive Summary
Bristol-Myers Squibb Co. and Johnson & Johnson’s Tibotec Pharmaceuticals Ltd. (the infectious disease division of Janssen Pharmaceutical Co.’s Janssen Pharmaceuticals Inc.) have agreed to create an all-oral regimen for chronic hepatitis C by combining their Phase III direct-acting antiretrovirals: BMS’s daclatasvir (BMS790052) with Tibotec’s TMC435.
Deal Industry
Pharmaceuticals
Deal Status
Final
Deal Type
Alliance
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?